![]() We have subsequently developed our technology further with regulatory approval for a suite of innovative devices for use with our CROMA advanced energy platform. This was followed by additional investment by Pentax Hoya and the Development Bank of Wales, which resulted in the first use of Speedboat Inject in a human case in 2015 and regulatory clearance from both the Food and Drug Administration and CE Mark in 2017, by which time, Richard Rees had joined in 2016 as CFO. In 2013, as Craig became Creo’s CEO, Finance Wales offered funding and support. However, he realised that a different approach would be required to take those prototypes to market and treat patients.Īt this point, Craig Gulliford came on board as an angel investor and helped raise seed capital and additional funding through government grants, which allowed further advancement of the technology, including initial animal studies. This allowed them to buy initial equipment, produce prototypes and begin to gain the company’s first patents. His original vision focused on a very R&D-led organisation, and the company was initially funded via a venture capital-backed UK incubator. Research continues into the possibilities offered to extend our capabilities, through the use of cool plasma and electroporation, into more wide-ranging fields including laparoscopy and sterilisation.įor founder and chief technology officer Chris Hancock, the driving purpose behind Creo is to help people to improve patient outcomes by leveraging, optimising, and controlling the right energy for the right reason. Our product range allows these energies to be utilised in the gastrointestinal tract, lungs, liver, and pancreas through miniature devices in minimally invasive treatments. Creo has harnessed the power of advanced bipolar radiofrequency and microwave energy to perform resection, dissection, haemostasis, and ablation. Professor Chris Hancock founded Creo Medical in 2003, initially to target the treatment of cancers through use of high-frequency microwave energy and dynamic matching techniques. What are the physics-based technologies that you are developing in your business? Creo’s first device, Speedboat Inject, is now in use worldwide, providing physicians with new treatment approaches and patients with life-changing outcomes. ![]() Creo Medical is focused on the development and commercialisation of technology and minimally invasive devices by bringing advanced energy to therapeutic endoscopy. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |